Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Addpharma

Status and phase: Completed; Phase 3

Conditions: Hypertension, Essential; Primary Hypercholesterolemia

Treatments: Drug: AD-2022 Placebo; Drug: AD-2021; Drug: AD-2022; Drug: AD-2021 Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06448962

AD-202P3

Details and patient eligibility

About

The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Full description

Condition or disease : Primary Hypercholesterolemia and Essential Hypertension Intervention/treatment Drug : AD-2021 Drug : AD-2022 Drug : AD-2021 Placebo Drug : AD-2022 Placebo Phase : Phase 3

Enrollment: 109 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Subjects with hypertension and hyperlipidemia

Exclusion criteria

• Patient with known or suspected secondary hypertension
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

109 participants in 3 patient groups

Experimental 1

Experimental group

Description:

AD-2021, AD-2022

Treatment:

Drug: AD-2022

Drug: AD-2021

Active Comparator 1

Active Comparator group

Description:

AD-2021, AD-2022 placebo

Treatment:

Drug: AD-2021

Drug: AD-2022 Placebo

Active Comparator 2

Active Comparator group

Description:

AD-2022, AD-2021 placebo

Treatment:

Drug: AD-2021 Placebo

Drug: AD-2022